These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15749173)

  • 1. Development of indications for cardiac resynchronisation therapy in the implantable cardioverter defibrillator population.
    Paisey JR; Yue AM; Moore R; Betts TR; Roberts PR; Morgan JM
    Int J Cardiol; 2005 Mar; 99(2):187-90. PubMed ID: 15749173
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcome of cardiac resynchronization therapy in patients with severe congestive heart failure.
    Davis DR; Krahn AD; Tang AS; Lemery R; Green MS; Gollob M; Yee R; Skanes AC; Klein GJ; Birnie DH
    Can J Cardiol; 2005 Apr; 21(5):413-7. PubMed ID: 15861258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation?
    Armoundas AA; Hohnloser SH; Ikeda T; Cohen RJ
    Nat Clin Pract Cardiovasc Med; 2005 Oct; 2(10):522-8. PubMed ID: 16186850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-pharmacological treatment of heart failure: implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy].
    van Gelder IC; Smit MD; Nieuwland W; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2238-44. PubMed ID: 17076357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sleep-disordered breathing on life-threatening ventricular arrhythmia in heart failure patients with implantable cardioverter-defibrillator.
    Serizawa N; Yumino D; Kajimoto K; Tagawa Y; Takagi A; Shoda M; Kasanuki H; Hagiwara N
    Am J Cardiol; 2008 Oct; 102(8):1064-8. PubMed ID: 18929710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Need and evolution of need for device therapy in a community heart failure population.
    Sulaiman HM; O'Loughlin C; Daly M; Conlon C; Ledwidge M; McCaffrey D; McDonald K
    Eur J Heart Fail; 2008 Jun; 10(6):601-7. PubMed ID: 18495532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices.
    Lin G; Rea RF; Hammill SC; Hayes DL; Brady PA
    Heart; 2008 Feb; 94(2):186-90. PubMed ID: 17761506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Tsai FS; Ahn C; Lai HM; Amin H; Gandhi K; Frishman WH; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):176-9. PubMed ID: 19617418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
    Moss AJ
    Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15900623
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive significance for sudden death of microvolt-level T wave alternans in New York Heart Association class II congestive heart failure patients: a prospective study.
    Baravelli M; Salerno-Uriarte D; Guzzetti D; Rossi MC; Zoli L; Forzani T; Salerno-Uriarte JA
    Int J Cardiol; 2005 Oct; 105(1):53-7. PubMed ID: 16207545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
    Buxton AE
    Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15897357
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy. The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study.
    Boriani G; Müller CP; Seidl KH; Grove R; Vogt J; Danschel W; Schuchert A; Djiane P; Biffi M; Becker T; Bailleul C; Trappe HJ;
    Am Heart J; 2006 May; 151(5):1050-8. PubMed ID: 16644335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years.
    Kleemann T; Becker T; Doenges K; Vater M; Senges J; Schneider S; Saggau W; Weisse U; Seidl K
    Circulation; 2007 May; 115(19):2474-80. PubMed ID: 17470696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification for sudden death in heart failure.
    Farwell D; Gollob MH
    Minerva Cardioangiol; 2007 Jun; 55(3):379-84. PubMed ID: 17534256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charge circuit timeout: a sequence of events leading to failure of an implantable cardioverter-defibrillator to deliver therapy.
    Catanzaro JN; Kim J; Patel A; Slotwiner D; Goldner B
    Circ Arrhythm Electrophysiol; 2011 Aug; 4(4):e33-5. PubMed ID: 21846878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.